PLYMOUTH, Minn., April 3 /PRNewswire-FirstCall/ -- ev3 Inc. today announced that Matthew Jenusaitis has joined the company as President of its Neurovascular Division. Jenusaitis is replacing Thomas Wilder who is leaving ev3 to pursue another career opportunity.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGO )
James Corbett, President and Chief Executive Officer of ev3, commented, “Since joining the ev3 family as President and CEO of Micro Therapuetics in 2002, Tom Wilder’s leadership has been critical to the emergence of our Neurovascular Division as a world-wide leader in its market. We are sorry to see him leave and wish him the best of luck in his new venture.”
Corbett continued, “However, we are very pleased and fortunate to have an executive with the proven record and experience of Matthew Jenusaitis join us as the new President of the ev3 Neurovascular Division.”
Jenusaitis is a graduate of Cornell University with a B.S. degree cum laude, a Master’s degree in biochemical engineering, cum laude, from Arizona State University, and an MBA degree from the University of California, Irvine. Jenusaitis has been in the medical device industry for over 20 years, including positions at Baxter Healthcare Corporation, SCIMED Life Systems, Inc. and Boston Scientific Corporation, most recently as President of Boston Scientific’s Peripheral Interventions business.
About ev3 Inc.
ev3 Inc. is a global medical device company focused on endovascular technologies for the minimally invasive treatment of vascular diseases and disorders.
Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties relate, but are not limited, to, in no particular order: product demand and market acceptance, the impact of competitive products and pricing, and success of clinical testing. More detailed information on these and additional factors which could affect ev3 Inc.'s operating and financial results are described in the company’s filings with the Securities and Exchange Commission, including its most recent quarterly report on Form 10-Q. ev3 Inc. urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces. Additionally, ev3 Inc. undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comev3 Inc.
CONTACT: Patrick Spangler, CFO of ev3 Inc., +1-763-398-7000,pspangler@ev3.net
